Form 4: Eton Pharmaceuticals Executive Awarded Restricted Stock Units

David Krempa, Chief Business Officer of Eton Pharmaceuticals, received 42,088 restricted stock units on October 2, 2024, vesting annually over four years.

Summary

• David Krempa, Chief Business Officer of Eton Pharmaceuticals, was granted 42,088 restricted stock units on October 2, 2024.
• These restricted stock units represent a contingent right to receive one share of ETON Common Stock each.
• The units will vest in four equal annual installments starting October 2, 2025, contingent upon Krempa's continued employment with the company.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and indicates confidence in the executive's ability to contribute to the company's success. However, the value is contingent on future performance.

Positives

• The grant of restricted stock units aligns the executive's interests with those of the shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued employment and commitment to the company's success.

Risks

• The value of the restricted stock units is dependent on the future performance of ETON Common Stock, which is subject to market fluctuations.
• If the reporting person ceases to be employed by the issuer, the unvested restricted stock units will be forfeited.

Future Outlook

The restricted stock units are designed to incentivize the executive to contribute to the future success and growth of Eton Pharmaceuticals.

Industry Context

Granting stock options and restricted stock units is a common practice in the pharmaceutical industry to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Stock-based compensation is a standard practice among publicly traded pharmaceutical companies.
• Companies like Amarin, Xeris, and Adamas also utilize stock options and restricted stock units as part of their executive compensation packages.
• The size and vesting schedule of the grant are likely benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• Shareholders may view the grant positively as it aligns executive interests with company performance.
• Employees may see it as a sign of the company's commitment to its leadership team.

Key Dates